Kevin Ostrowski, MD
Urology · Kirkland, WANPI 1033352794
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (37.2%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Coloplast accounts for 70.3% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $31,220 and has fallen 98.8% since, to $372 in 2025. Among urology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 170 payments — averaging $377.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$45K
- Boston Scientific$18K
- 180 Medical, Inc.$391
- AbbVie$113
- Progenics Pharmaceuticals, Inc.$90
- Urogen Pharma, Inc.$75
- plus $580 from 19 others
What the payments were for
- Consulting fees$9,06314%
- Speaking & faculty fees$10,85017%
- Travel & lodging$16,13325%
- Food & beverage$4,2277%
- Education$23,83237%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 74 | $45,074 |
| Boston Scientific | 48 | $17,781 |
| 180 Medical, Inc. | 14 | $391 |
| AbbVie | 1 | $113 |
| Progenics Pharmaceuticals, Inc. | 4 | $90 |
| Urogen Pharma, Inc. | 3 | $75 |
| Laborie Medical Technologies Corp. | 3 | $70 |
| Tolmar Pharmaceuticals, Inc. | 3 | $63 |
| Sumitomo Pharma America, Inc. | 2 | $56 |
| Ferring Pharmaceuticals Inc. | 1 | $46 |
| Tolmar, Inc. | 2 | $40 |
| Myovant Sciences Inc. | 2 | $34 |
| Blue Earth Diagnostics | 1 | $34 |
| Endo USA, Inc. | 1 | $27 |
| Astellas Pharma US Inc | 1 | $26 |
| EDAP Technomed Inc | 1 | $25 |
| Calyxo, Inc. | 1 | $24 |
| Angiodynamics, Inc. | 1 | $23 |
| Axonics, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Immunitybio, Inc. | 1 | $19 |
| Endo Pharmaceuticals Inc. | 1 | $17 |
| EMD Serono, Inc. | 1 | $16 |
| Dentsply IH AB | 1 | $15 |
| Travere Therapeutics, Inc. | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$33,223
- AMS$11,854
- ALTIS$10,310
- ADVANCE$4,160
- GENERAL - THERAPIES$866
- Lupron Depot$113
How this compares
$64,105 in reported general payments places this provider in the 95th percentile of 274 urology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 48 | $25,041 |
| GemtesaVibegron | 11 | $7,127 |
| Testosterone | 20 | $3,699 |
| Tamsulosin Hcl | 151 | $2,826 |
| Testosterone Cypionate | 25 | $1,381 |
| Finasteride | 38 | $561 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 22 | $153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $26 | $25,04148 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $56 | $7,12711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 274 urology providers in Washington.
Other urology in Kirkland
- Sabrina StairKirkland$9K
- James PorterSeattle$471K
- Marah HehemannSeattle$213K
- Raymond LanceSpokane$211K
- Thomas WalshSeattle$186K
- Alvaro LucioniSeattle$148K
- Una LeeSeattle$116K
- George SchadeSeattle$78K
- Marco SalazarEdmonds$58K
- Anthony BuiVancouver$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.